Nektar Therapeutics Q1 2024 Earnings Report $0.83 -0.02 (-2.74%) As of 01/31/2025 04:00 PM Eastern Earnings HistoryForecast Nektar Therapeutics EPS ResultsActual EPS-$0.18Consensus EPS -$0.21Beat/MissBeat by +$0.03One Year Ago EPS-$0.25Nektar Therapeutics Revenue ResultsActual Revenue$21.64 millionExpected Revenue$14.91 millionBeat/MissBeat by +$6.73 millionYoY Revenue GrowthN/ANektar Therapeutics Announcement DetailsQuarterQ1 2024Date5/9/2024TimeAfter Market ClosesConference Call ResourcesConference CallConference Call TranscriptPress ReleaseNKTR Earnings HistoryConference Call AudioYour browser does not support the audio element. Listen Now.Powered by Nektar Therapeutics Earnings HeadlinesNektar Therapeutics: Promising Drug Pipeline and Strategic Expansion Drive Buy RatingJanuary 13, 2025 | markets.businessinsider.comBuy Rating for Nektar Therapeutics: Promising Clinical Trial Strategy and Efficacy of RezpegJanuary 12, 2025 | markets.businessinsider.comElon’s #1 AI Stock” SET TO SOARForget ChatGPT! Because Elon Musk's AI promises to be 100x more powerful.February 1, 2025 | Behind the Markets (Ad)Nektar completes enrollment in REZOLVE-AD Phase 2b study of rezpegaldesleukinJanuary 10, 2025 | markets.businessinsider.comNektar Therapeutics (NKTR) Gets a Buy from Piper SandlerJanuary 10, 2025 | markets.businessinsider.comNektar Therapeutics Announces Completion of Target Enrollment in REZOLVE-AD Phase 2b Clinical ...January 10, 2025 | gurufocus.comSee More Nektar Therapeutics Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Nektar Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Nektar Therapeutics and other key companies, straight to your email. Email Address About Nektar TherapeuticsNektar Therapeutics (NASDAQ:NKTR), a biopharmaceutical company, focuses on discovering and developing medicines in the field of immunotherapy in the United States and internationally. The company is developing rezpegaldesleukin, a cytokine Treg stimulant that is in phase 2 clinical trial for the treatment of systemic lupus erythematosus and ulcerative colitis, as well as phase 2b clinical trial to treat atopic dermatitis and psoriasis; and NKTR-255, an IL-15 receptor agonist, which is in phase 1 clinical trial to boost the immune system's natural ability to fight cancer. It has collaboration agreements with Takeda Pharmaceutical Company Ltd.; AstraZeneca AB; UCB Pharma S.A.; F. Hoffmann-La Roche Ltd; Bausch Health Companies Inc.; Pfizer Inc.; Amgen Inc.; UCB Pharma (Biogen); Bristol-Myers Squibb Company; Merck KGaA; and SFJ Pharmaceuticals, Inc. The company was incorporated in 1990 and is headquartered in San Francisco, California.View Nektar Therapeutics ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Earnings By Country U.S. Earnings Reports Canadian Earnings Reports U.K. Earnings Reports Latest Articles Why Amazon’s Next Earnings Could Trigger a Stock BreakoutS&P 500 Earnings Set to Shine: January's Critical Market TestCiena Rebounds: AI and Strong Guidance Drive Post-Earnings SurgeHistory Hints at a Rebound for Toll Brothers After EarningsAlibaba Stock: Why Earnings Make It a Buy Despite the Recent DipMercadoLibre Down 23% After Missed Earnings: Time to Buy the Dip?Roblox Stock Soars 22% After Q3 Earnings – A Turning Point Ahead? Upcoming Earnings PayPal (2/3/2025)Palantir Technologies (2/3/2025)NXP Semiconductors (2/3/2025)Mitsubishi UFJ Financial Group (2/3/2025)Mondelez International (2/4/2025)Advanced Micro Devices (2/4/2025)Alphabet (2/4/2025)Alphabet (2/4/2025)Amgen (2/4/2025)Banco Bilbao Vizcaya Argentaria (2/4/2025) Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
